Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shou Zu Ning No. 2 is a Traditional Chinese Medicine (TCM) herbal formula developed for the management of hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia. HFS is a frequent dermatological toxicity associated with chemotherapy agents like capecitabine and multi-kinase inhibitors such as sorafenib. The formula is typically used as a topical soak or wash, designed to alleviate symptoms including erythema, edema, pain, and skin cracking. Its therapeutic rationale is based on TCM principles of clearing heat, detoxifying, and invigorating blood circulation to resolve local stasis and inflammation. Clinical research, primarily conducted in China, suggests that Shou Zu Ning No. 2 can effectively reduce the incidence and severity of HFS, thereby supporting the continuation of primary oncological treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shou Zu Ning No. 2.